Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Pfizer (PFE) Stock Forecast & Price Target

Pfizer logo
$24.74 -0.33 (-1.33%)
As of 10:08 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

Pfizer - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 18 Analyst Ratings
Sell
1
Hold
11
Buy
6

Based on 18 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 1 has given a sell rating, 11 have given a hold rating, 4 have given a buy rating, and 2 have given a strong buy rating for PFE.

Consensus Price Target

$28.12
13.67% Upside
According to the 18 analysts' twelve-month price targets for Pfizer, the average price target is $28.12. The highest price target for PFE is $33.00, while the lowest price target for PFE is $23.00. The average price target represents a forecasted upside of 13.67% from the current price of $24.74.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PFE Analyst Ratings Over Time

TypeCurrent Forecast
8/28/24 to 8/28/25		1 Month Ago
7/29/24 to 7/29/25		3 Months Ago
5/30/24 to 5/30/25		1 Year Ago
8/29/23 to 8/28/24
Strong Buy
2 Strong Buy rating(s)
3 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
11 Hold rating(s)
13 Hold rating(s)
13 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$28.12$28.55$28.55$34.54
Forecasted Upside13.67% Upside17.51% Upside21.70% Upside20.11% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pfizer Stock vs. The Competition

TypePfizerMedical CompaniesS&P 500
Consensus Rating Score
2.39
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside12.13% Upside14,610.39% Upside9.99% Upside
News Sentiment Rating
Positive News

See Recent PFE News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/6/2025Citigroup
2 of 5 stars		Andrew Baum
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetNeutral ➝ Neutral$25.00 ➝ $26.00+8.57%
8/6/2025Morgan Stanley
3 of 5 stars		Terence Flynn
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetEqual Weight ➝ Equal Weight$32.00 ➝ $33.00+37.75%
8/6/2025Bank of America
4 of 5 stars		Tim Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetNeutral ➝ Neutral$27.00 ➝ $28.00+13.41%
5/29/2025Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetHold$28.00 ➝ $25.00+6.66%
5/21/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$32.00 ➝ $33.00+43.11%
5/19/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$27.00 ➝ $26.00+12.99%
4/30/2025Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetUnderperform$22.00 ➝ $23.00-5.78%
4/30/2025Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral$29.00 ➝ $27.00+10.61%
4/30/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetMarket Perform$28.00 ➝ $26.00+6.51%
4/30/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		C. Shibutani
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetNeutral$25.00 ➝ $27.00+10.61%
4/30/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Trung Huynh
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetNeutral ➝ Neutral$24.00 ➝ $25.00+3.55%
4/22/2025TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetHold$32.00 ➝ $28.00+24.22%
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOverweight ➝ Neutral$24.00+8.74%
4/17/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$36.00 ➝ $30.00+35.57%
3/18/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Vamil Divan
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy
3/10/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating		R. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeStrong-Buy
12/18/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$36.00 ➝ $32.00+21.72%
10/30/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		U. Raffat
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeStrong-Buy
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageMarket Perform$32.00+7.89%
8/7/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeModerate Buy ➝ Strong-Buy
8/7/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Outperform$28.00 ➝ $34.00+14.21%
7/31/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$30.00 ➝ $32.00+4.51%
7/31/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $30.00-3.23%
3/22/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
10/16/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$36.00 ➝ $34.00+0.71%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:09 AM ET.


Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, August 27, 2025. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • The company recently reported a quarterly revenue increase of over 10%, indicating strong growth and demand for its products.
  • Pfizer Inc. has set its FY 2025 earnings per share guidance between 2.900 and 3.100, suggesting a positive outlook for profitability.
  • The current stock price is around $24.97, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. has a robust dividend yield of approximately 6.8%, providing a steady income stream for investors.
  • The company has a strong market presence with a diverse portfolio of products, including recent advancements in COVID-19 treatments and vaccines.

Pfizer
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • The stock has experienced fluctuations, with a 52-week high of $30.43 and a low of $20.92, indicating potential volatility.
  • Analysts currently rate Pfizer Inc. as a "Hold," suggesting that there may not be strong upward momentum in the stock price.
  • The company's high dividend payout ratio of 91.49% may raise concerns about sustainability, as it indicates that a large portion of earnings is being distributed to shareholders.
  • Pfizer Inc. operates in a highly competitive biopharmaceutical market, which could impact its market share and profitability.
  • Recent earnings per share were reported at $0.78, which, while beating estimates, may not be sufficient to drive significant investor confidence moving forward.

PFE Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $28.12, with a high forecast of $33.00 and a low forecast of $23.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There is currently 1 sell rating, 11 hold ratings, 4 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.

According to analysts, Pfizer's stock has a predicted upside of 13.67% based on their 12-month stock forecasts.

Pfizer has been rated by research analysts at Bank of America, Citigroup, and Morgan Stanley in the past 90 days.

Analysts like Pfizer less than other "medical" companies. The consensus rating for Pfizer is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PFE compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:PFE) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...
Banyan Hill Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...
Investors Alley | Sponsoredtc pixel
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...
Reagan Gold Group | Sponsoredtc pixel
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...
Paradigm Press | Sponsoredtc pixel
How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...
Brownstone Research | Sponsoredtc pixel